Eleven Biotherapeutics (EBIO) Misses Q2 EPS by 8c

Eleven Biotherapeutics (NASDAQ: EBIO) reported Q2 EPS of ($0.36), $0.08 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $114 thousand versus the consensus estimate of $200 thousand.

For earnings history and earnings-related data on Eleven Biotherapeutics (EBIO) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• MP Materials seen largely insulated after China export-control move
• AXT appoints Tracy Liu to its board of directors